Doxorubicin (DOX) is widely used in cancer therapy. However, its application is sometimes limited by its adverse cardiotoxicity and delivery pathways. In our study, we prepared a topical implantable delivery device for controlled drug release and site-specific treatment. The core region consisted of poly (lactic co-glycolic acid) and poly-caprolactone, whereas the shell region was composed of cross-linked gelatin. DOX was enclosed in the core region of a core-shell nanofiber obtained by electrospinning. This implantable delivery device was implanted on the top of the melanoma in a mouse model, which had shown a DOX-controlled release profile with sustained and sufficient local concentration against melanoma growth in mice with negligible side effects. Compared with the traditional intravenous administration, the implantable device allows precisely localized treatment and therefore can reduce the dose, decrease the injection frequency, and ensure antitumor efficacy associated with lower side effects to normal tissues. Using a coaxial electrospinning process, it is promising to deliver different hydrophobic or hydrophilic drugs for direct tumor site-specific therapy without large systemic doses and minimized systemic toxicity.

阿霉素 (DOX) 广泛用于癌症治疗。然而，它的应用有时会受到其不利的心脏毒性和传递途径的限制。在我们的研究中，我们准备了一种用于控制药物释放和特定部位治疗的局部植入式给药装置。核心区域由聚（乳酸co-乙醇酸）和聚己内酯，而壳区域由交联明胶组成。DOX 被封闭在通过静电纺丝获得的核-壳纳米纤维的核心区域中。这种植入式递送装置被植入小鼠模型中黑色素瘤的顶部，该装置显示出 DOX 控制释放曲线，具有持续和足够的局部浓度，可防止小鼠黑色素瘤生长，副作用可忽略不计。与传统的静脉给药相比，植入式装置可以实现精确的局部治疗，因此可以减少剂量，减少注射频率，确保抗肿瘤疗效，同时对正常组织的副作用较小。使用同轴静电纺丝工艺，